Zymeworks (ZYME) Tops Q4 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
February 24, 2022 4:15 PM ESTEnrollment on track for both pivotal trials of zanidatamab in 1L gastroesophageal adenocarcinoma (GEA) and 2L biliary tract cancer (BTC). Announced submission of abstracts for upcoming clinical data for the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting. Financial position strengthened and cash runway extended following successful completion of equity offering in January. Announced Chris Astle, PhD as new Chief Financial Officer, with Neil Klompas continuing as Chief Operating Officer. Expected to exceed the previously announced workforce reduction of at least 25% by March 1, 2022, ahead of... More
